Vol. 11 No. Suppl. 2 (2024): Treating Gram-Positive infections in the antimicrobial resistance era: Clinical and economic role of dalbavancin

Published: 2024-07-29

Editorial (on invitation only)

Original Research Articles

  • Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease network

    Daniela Segala, Marco Barbieri, Mariachiara Di Nuzzo, Melissa Benazzi, Aurora Bonazza, Letizia Romanini, Brunella Quarta, Kristian Scolz, Anna Marra, Diana Campioni, Rosario Cultrera
    5-12
    DOI: https://doi.org/10.33393/grhta.2024.3094

  • The efficacy of dalbavancin and impact on hospitalization and treatment costs in patients with ABSSSI

    Sergio Carbonara
    13-17
    DOI: https://doi.org/10.33393/grhta.2024.3045

  • Usefulness of dalbavancin in early discharge and non-hospitalization. It’s time to throw your heart over the obstacle?

    Massimo Crapis, Sergio Venturini, Astrid Callegari, Giovanni Del Fabro, Igor Bramuzzo, Laura De Santi, Elisa Pontoni, Maurizio Tonizzo, Barbara Basso
    18-21
    DOI: https://doi.org/10.33393/grhta.2024.3071